EdiGene Announces Clinical Sites Activation and First Patient Enrolled in Multicenter Phase I Clinical Trial of its Investigational Gene-editing Hematopoietic Stem Cell Therapy ET-01 for Patients with Transfusion Dependent ?-thalassemia
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc. (“Company”, or “EdiGene”), today announced the first patient enrolled…